HighTower Advisors LLC Reduces Stock Holdings in Eli Lilly and Company $LLY

HighTower Advisors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 487,722 shares of the company’s stock after selling 18,411 shares during the period. Eli Lilly and Company accounts for approximately 0.6% of HighTower Advisors LLC’s holdings, making the stock its 24th biggest holding. HighTower Advisors LLC’s holdings in Eli Lilly and Company were worth $524,145,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $33,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares in the last quarter. Dorato Capital Management bought a new position in Eli Lilly and Company in the fourth quarter worth about $36,000. Finally, New England Capital Financial Advisors LLC lifted its holdings in Eli Lilly and Company by 142.9% in the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 1.6%

Eli Lilly and Company stock opened at $988.76 on Tuesday. The business’s fifty day moving average is $940.00 and its 200 day moving average is $999.39. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $931.15 billion, a PE ratio of 35.12, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, May 1st. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Jefferies Financial Group set a $1,300.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research report on Friday, March 13th. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,218.33.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.